Daiichi Sankyo Company, Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| D4S.F | CUP.F | YPH.F | 4552.T | BIIB | ON4.F | |
|---|---|---|---|---|---|---|
| Market cap | 31.06B | 65.86B | 26.36B | 64.55B | 37.61B | 6.28B |
| P/E (TTM) | 20.3 | 24.0 | 13.0 | — | 110.2 | 15.4 |
| Forward P/E | 46.1 | 0.3 | — | 14.4 | 15.6 | — |
| Price/book | 3.1 | 5.6 | 2.4 | 1.6 | 2.0 | 1.3 |
| Dividend yield | 3.57% | 1.93% | 3.17% | 3.97% | — | 3.63% |
| 1-year change | −17.43% | −1.62% | +51.13% | −17.24% | +62.35% | +18.01% |
| Today | +5.64% | +4.33% | +5.76% | +4.96% | +2.22% | +4.90% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All D4S.F news ›Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing openPR.com Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma,…
Comparing Daiichi Sankyo (DSNKY) and The Competition
Posted by Michael Walen on Nov 3rd, 2026 Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Daiichi Sankyo to…
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. Q2 FY2026 Results Global revenue increased 19.7% year-over-year to 1.167 trillion yen,…
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call October 30, 2026 4:30 AM EDT Ari Fujishiro - Corporate Officer & Head of IR & SR Dept., Global Corporate AffairsHiroyuki Okuzawa - President, CEO & Representative DirectorKen…
Daiichi Sankyo reports Q2 results; reaffirms FY2026 outlook
Daiichi Sankyo Q2 revenue rose 19.7% as global oncology medicines fueled growth. - Daiichi Sankyo press release (DSKYF): Q2 global revenue increased 19.7% year-over-year to 1.167 trillion yen, driven by the company’s global oncology…
Daiichi Sankyo, AstraZeneca's Datroway Gets China's Approval for Second Breast Cancer Indication
Daiichi Sankyo and UK-headquartered global biopharmaceutical company AstraZeneca have received approval for a second indication for their cancer treatment, Datroway, in China, according to a... Daiichi Sankyo Company, Limited Daiichi…
AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types
AstraZeneca PLC and Daiichi Sankyo entered into a clinical collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway in combination with ivonescimab across multiple tumour types... AstraZeneca PLC and Daiichi Sankyo…
AstraZeneca, Daiichi Sankyo to Evaluate Datroway Combo Across Tumor Types with Summit Therapeutics
Published on 10/02/2026 at 05:30 am EDT Two favorable EU opinions for AstraZeneca September 21, 2026 at 05:06 am EDT AstraZeneca: Share price weakness of late, should be capitalised on AstraZeneca Is Said to Have Explored Bristol Myers…
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 30 abstracts, including four late breaking presentations, in multiple cancers at the 2026 European Society…
Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact
Albany New York October 22 2026 As per DelveInsight s assessment globally Ovarian Cancer pipeline constitutes 180 key companies continuously working towards developing 200 Ovarian Cancer treatment therapies analysis of Clinical Trials…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- seekingalpha.com4
- openpr.com1
- pmlive.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.